Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

2(22%)

Results Posted

83%(5 trials)

Phase Distribution

Ph phase_3

11%

Ph phase_2

78%

Ph phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

1(11.1%)

Phase 2Efficacy & side effects

7(77.8%)

Phase 3Large-scale testing

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(6)

Terminated(1)

Detailed Status

Completed6

Withdrawn1

Recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (11.1%)

Phase 27 (77.8%)

Phase 31 (11.1%)

Trials by Status

completed667%

withdrawn111%

recruiting111%

active_not_recruiting111%

Recent Activity

2 active trials

Showing 5 of 9

recruitingphase_2

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

NCT05933499

completedphase_1

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

NCT06890611

active_not_recruitingphase_2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728

withdrawnphase_2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

NCT06901349

completedphase_2

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT05933499Phase 2

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

Recruiting

NCT06890611Phase 1

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Completed

NCT06643728Phase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Active Not Recruiting

NCT06901349Phase 2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Withdrawn

NCT05616013Phase 2

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Completed

NCT02333331Phase 2

Dose Range Finding Study of Bimagrumab in Sarcopenia

Completed

NCT02152761Phase 2

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Completed

NCT02468674Phase 2

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Completed

NCT02573467Phase 3

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9